-
公开(公告)号：EP4349342A1
公开(公告)日：2024-04-10
申请号：EP22926321.5
申请日：2022-11-09
发明人： KIM, Young Ho , PARK, Shin Young , JANG, Won Young
摘要： The present disclosure relates to an immunosuppressive composition containing 3,6-anhydro-L-galactose (L-AHG) as an active ingredient, and a pharmaceutical composition for preventing or treating immunological diseases, a health functional food for preventing or ameliorating immunological diseases, and a functional cosmetic composition for preventing or ameliorating hypersensitivity skin reactions, which contain the active ingredient. The immunosuppressive composition, pharmaceutical composition, health functional food, and functional cosmetic composition containing L-AHG according to the present disclosure have an excellent effect of selectively and effectively inhibiting the activation, proliferation and differentiation of CD4 T cells, which are the main targets of immunosuppressants, and thus are very useful in the pharmaceutical industry, the food industry and the cosmetic industry.
-
公开(公告)号：EP4324486A1
公开(公告)日：2024-02-21
申请号：EP22788248.7
申请日：2022-02-18
申请人： Kyungpook National University Industry-Academic Cooperation Foundation , Daegu Gyeongbuk Institute Of Science and Technology
IPC分类号： A61K48/00 , A61K31/713 , A61P35/00 , G01N33/50 , C12N15/113 , C07K16/28
摘要： The present invention relates to use of an odorant receptor for suppressing the lactate-induced M2-type differentiation of tumor-associated macrophages and tumor growth. In particular, the inventors of the present invention assumed that lactate-activated OR Olfr78 would function as a macrophage lactate sensor, and confirmed whether Olfr78 on bone marrow-derived macrophages (BMDMs) detect tumor-derived lactate and lactate-induced M2 polarization. The inventors of the present invention attempted to identify factors detected by Olfr78 in tumor conditioned media (TCM), and discovered that lactate in TCM and acetic acid under some conditions are major factors involved in Olfr78-mediated generation of tumor-friendly M2-TAMs. Finally, it was found that Olfr78 deficiency inhibited tumor progression and metastasis and improved antitumor immunity in vivo (in vivo). According to the present invention, Olfr78-lactate interaction plays a major role in tumor progression, and thus, targeting of the Olfr78-lactate axis can be effectively used in targeted cancer therapy.
-
公开(公告)号：EP4260686A1
公开(公告)日：2023-10-18
申请号：EP21915676.7
申请日：2021-12-23
发明人： LEE, Je Min
摘要： The present invention relates to a wild-type-derived introgression line of a tomato in which the expression of BC2.1 is inhibited and the amount of beta-carotene or lutein is increased; and a transgenic tomato.
-
4.发明公开
公开(公告)号：EP4230119A1
公开(公告)日：2023-08-23
申请号：EP23156482.4
申请日：2023-02-14
申请人： Huvitz Co., Ltd. , Ossvis Co., Ltd. , Kyungpook National University Industry-Academic Cooperation Foundation
发明人： JEONG, Hyo Sang , HAN, Su Min , KIM, Jee Hyun , LEE, Kyu Bok , SON, Keun Ba Da , LEE, Weon Joon
IPC分类号： A61B5/00
摘要： Disclosed are an intraoral scanner having a tomographic imaging function capable of inspecting the state of cracks in oral structures such as teeth and dental filling materials, and a method for detecting cracks in oral structures using the same. The intraoral scanner having a tomographic imaging function comprises: an OCT body (6) configured to obtain an internal cross-sectional image of an oral structure (T) by transmitting layer measurement light through the oral structure (T) and detecting reflected light reflected by a surface and an inside of the oral structure (T); an OCT scan probe (8) configured to irradiate the layer measurement light emitted from the OCT body (6) onto the oral structure (T) and transfer the reflected light reflected from the oral structure (T) to the OCT body (6); and a control/processing unit (48) configured to control the OCT body (6), take a tomographic image of the oral structure (T) while proceeding in a predetermined direction along the surface of the oral structure (T), obtain two or more two-dimensional cross-sectional images of the oral structure (T), extract an internal crack area for the respective two-dimensional cross-sectional images obtained, calculate cross-sectional position information of the internal crack, then arrange the position information of the internal crack obtained from the respective two-dimensional cross-sectional images in positions where the respective two-dimensional cross-sectional images have been obtained, and obtain three-dimensional shape information of the internal crack.
-
公开(公告)号：EP4218757A1
公开(公告)日：2023-08-02
申请号：EP21872859.0
申请日：2021-09-17
发明人： BAE, Jae Sung , JIN, Hee Kyung , PARK, Min Hee
IPC分类号： A61K31/4192 , A23L33/10 , C07D249/04
摘要： The present invention relates to a use of a triazole compound as a ghrelin receptor agonist and, more specifically, to a composition for preventing or treating diseases mediated by the ghrelin receptor, the composition being of a triazole compound which strongly binds to the ghrelin receptor with very high specificity. The compound provided by the present invention exhibits a strong binding force to the ghrelin receptor with very high specificity, and thus may be very usefully employed for preventing or developing a therapeutic agent for diseases mediated by the ghrelin receptor.
-
6.发明公开
公开(公告)号：EP4209586A1
公开(公告)日：2023-07-12
申请号：EP21864679.2
申请日：2021-09-02
申请人： Daegu Gyeongbuk Institute Of Science and Technology , Kyungpook National University Industry-Academic Cooperation Foundation
发明人： BAEK, Moon-Chang , YEA, Kyung Moo , CHO, Hanchae
摘要： The present invention relates to an extracellular vesicle expressing a cytokine and an antibody, a method for producing same, and a use thereof. The present invention provides a method for producing an immune cell expressing both a cytokine and an antibody on membrane surface by transforming them with a first vector encoding a cytokine and a second vector encoding an antibody, and producing their extracellular vesicle expressing both a cytokine and an antibody on the surface. The present invention provides the extracellular vesicle which induces a desired cytokine response in cells that can be targeted with a specific antibody and is safe for the human body while exhibiting excellent anticancer effects. The present invention provides a new cancer treatment means that deliver drugs or physiologically active substances to specific cancer cells by loading a drug or physiologically active substance that exhibits a therapeutic effect on cancer in the extracellular vesicle.
-
公开(公告)号：EP4198042A1
公开(公告)日：2023-06-21
申请号：EP21856228.8
申请日：2021-08-11
发明人： LEE, Byung-Heon , CHAE, Youngji , KHAN, Fatima , VADEVOO, Sri Murugan Poongkavithai , GUNASSEKARAN, Gowri Rangaswamy
IPC分类号： C07K14/00 , C07K7/08 , G01N33/574 , A61K47/42 , A61K31/704 , A61K38/00 , A61K51/08
摘要： The present invention relates to a peptide selectively binding to a cancer cell-derived exosome, and uses thereof. A peptide of ExoPep (CRKVAKG) has been discovered using a phage display technique to discover a peptide with specific binding ability to an exosome derived from cancer cells. The peptide binds to a cancer cell-derived exosome having a property of moving to a cancer site and a cancer metastasis site, and thus may have the effect of delivering an anticancer drug to the cancer metastasis site.
-
8.发明公开
公开(公告)号：EP4095143A1
公开(公告)日：2022-11-30
申请号：EP21745126.9
申请日：2021-01-22
发明人： CHANG, Yong Min , SUNG, Bo Kyung
摘要： The present invention relates to a novel gadolinium-based compound having a structure in which a gadolinium complex and a gallic acid are bonded to each other, a method for producing same, and an MRI contrast agent containing same.
-
公开(公告)号：EP4043019A1
公开(公告)日：2022-08-17
申请号：EP20875550.4
申请日：2020-09-18
申请人： Kyungpook National University Industry-Academic Cooperation Foundation , Daegu Gyeongbuk Institute Of Science and Technology
发明人： BAEK, Moon-Chang , YEA, Kyungmoo , JUNG, Do Kyung , RYU, Suyeon , SHIN, Sang Hee , JUNG, In Seong
IPC分类号： A61K35/17 , A61P35/00 , C12N5/0783
摘要： The present invention relates to a composition, for prevention or treatment of cancer diseases, comprising CD8+ T cells activated by CD4+ T cell-derived extracellular vesicles as an active ingredient. It was found that the secretion of extracellular vesicles from cytokine-activated CD4+ T cells increases and the extracellular vesicles enhance proliferation and activity of CD8+ T cells to induce the death of cancer cells, thereby augmenting an anticancer effect. Thus, the present invention provides the CD8+ T cells activated by CD4+ T cell-derived extracellular vesicles as a pharmaceutical agent or an immunotherapeutic agent for cancer diseases, and a method for activating CD8+ T cells by using CD4+ T cell-derived extracellular vesicles to prepare CD8+ T cells showing excellent anticancer activity as described above.
-
公开(公告)号：EP3732524A1
公开(公告)日：2020-11-04
申请号：EP19756624.3
申请日：2019-02-20
申请人： Samsung Electronics Co., Ltd. , Kyungpook National University Industry-Academic Cooperation Foundation
发明人： YOON, Chiyul , PARK, Jonghoo
-
-
-
-
-
-
-
-
-
搜索结果
155 条记录 (耗时 0.023 秒)
